Description
Harvoni (Ledipasvir/Sofosbuvir) 90mg/400mg Online
Harvoni (Ledipasvir/Sofosbuvir) is an antiviral medication that prevents hepatitis C virus (HCV) cells from multiplying in your body. Harvoni is a combination medicine used to treat hepatitis C in adults. The combination of ledipasvir and sofosbuvir is used alone or in combination with ribavirin (Copegus, Rebetol, Ribasphere, others) to treat certain types of chronic hepatitis C (an ongoing viral infection that damages the liver) in adults and children 3 years of age and older. Sofosbuvir is in a class of antiviral medications called nucleotide polymerase inhibitors. It works by decreasing the amount of hepatitis C virus (HCV) in the body. Ledipasvir is in a class of antiviral medications called HCV NS5A inhibitors. It works by stopping the virus that causes hepatitis C from spreading inside the body.
Chronic hepatitis C: Treatment of chronic hepatitis C virus genotype 1, 4, 5, or 6 infections in adult and pediatric patients ≥3 years of age, without cirrhosis or with compensated cirrhosis; genotype 1 in adult patients with decompensated cirrhosis, in combination with ribavirin; and genotype 1 or 4 in adult liver transplant patients without cirrhosis or with compensated cirrhosis, in combination with ribavirin.
Chronic hepatitis C, genotype 1 or 4 (kidney transplant recipients) Based on the AASLD/IDSA Recommendations for Testing, Managing, and Treating Hepatitis C guidelines, Harvoni is recommended and effective for the treatment of hepatitis C virus genotype 1 or 4 infections in kidney transplant recipients without cirrhosis or with compensated cirrhosis. Hepatitis C treatment guidelines are constantly changing with the advent of new treatment therapies and information; consult current clinical practice guidelines for the most recent treatment recommendations.
